To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
116 Current news of BASFrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
White biotechnology is becoming an increasingly important part of BASF’s toolbox
At BASF, innovation and sustainability are inextricably linked. Researchers worldwide are working on innovative solutions to tap alternative raw material sources and to develop climate-friendly production processes and products. Current research projects and examples of innovation for various ...
RiKarbon’s innovative technologies facilitate commercial production of renewable chemicals and high-performing ingredients
BASF and RiKarbon Inc., a U.S.-based technology start-up, announce the signing of a partnership contract to exclusively license and commercialize proprietary technology from RiKarbon. RiKarbon’s patented technology allows the upcycling of bio-waste into bio-based, biodegradable emollients for ...
First product facilitates reliable and reproducible 3D cell cultivation
Mannheim-based life science startup faCellitate has successfully raised 3.7 million Euro in its closing of seed funding. On board are well-known investors such as SARSTEDT, HTGF, R3 Consulting, ROI Verwaltungsgesellschaft, ARVE Capital and Chemovator. The faCellitate team under the leadership of ...
BASF Corporation announced the appointment of JeffreyDeAlmeida to the role of Senior Vice President, Pharma Solutions and Nutrition & Health Americas, effective March 1, 2022. He succeeds Christian Seufert, who has decided to transition to a role outside the company. In this role, Jeffrey ...
New herbicides inhibit the growth of herbicide-resistant weeds and invasive plants
BASF Venture Capital GmbH (BVC) and Orbia Ventures today announce their Series-B investment in the Israeli biotech startup FortePhest. Founded in 2017, FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants. Inspired and informed by natural plant ...
Success for long-standing collaboration between BASF and Givaudan to develop and validate alternative methods
The world’s first toxicology testing strategy without animal testing has been approved by the OECD (Organisation for Economic Co-operation and Development). The testing strategy consists of three so-called alternative methods. They can be used to predict whether a substance causes allergic ...
LanzaTech and BASF achieve first milestone in utilizing industrial off-gases for chemical production
Transforming the carbon contained in industrial off-gases into valuable chemicals is the aim of a partnership between LanzaTech and BASF. Now the partners have achieved a key first success: With the help of special bacteria, they have been able to produce n-octanol at laboratory scale from carbon ...
BASF will invest at Novartis’ Kundl/Schaftenau Campus, in Austria
On April 26, 2021 BASF has agreed with Sandoz GmbH, a subsidiary of Novartis, to invest at the Kundl/Schaftenau Campus in Austria. This agreement enables BASF to further develop its production footprint for enzymes and biotechnology products. Both parties agreed not to disclose financial details ...
Bota Bio’s next-generation industrial biology platform is a combination of computation and cutting-edge biotechnology
BASF Venture Capital (BVC) has invested in Bota Biosciences, Ltd. (Bota Bio), an industrial synthetic biotech company based in Hangzhou, China. Bota Bio, founded in 2019, is developing a proprietary next-generation biotechnology platform which enables sustainable and economical production of high ...
BASF provides research groups free access to substances from its compound library comprising several million entries
BASF is also providing support worldwide to academic research groups in their search for a suitable active ingredient to treat patients infected with the coronavirus. “We do not develop active pharmaceutical ingredients, but BASF has more than 150 years of experience in researching substances. ...